Liquid Segment has the Largest Share of State of Finished Products in the Europe Pharmaceutical Fill and Finish Outsourcing Market during 2021–2028

According to our latest study on “Europe Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028 – COVID-19 Impact and Analysis – by State of Finished Products, and Content,” the market is projected to reach US$ 1,295.0 million by 2028 from US$ 865.4 million in 2021; it is expected to grow at a CAGR of 5.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars. However, complex processes and high cost of production critically impacts the growth of the market.

The onset of COVID-19 pandemic impacted severely Europe pharmaceutical companies’ organizational performance in terms of production and sales. For example, German regulatory bodies impose price cut measures, causing slower growth in the solid dose formulation segment. However, demand for contract manufacturing accelerated during the onset of pandemic in Europe. Among EU, Germany is likely to remain as the largest contract manufacturing market in Western Europe, both in terms of capacity and market share. Also, during the pandemic, Europe accounted considerable market in terms of pharmaceutical fill and finish outsourcing due to large number of clinical trials in this region, huge API production base, advanced manufacturing capability, presence of leading pharmaceutical companies, and growth in generics market. Manufacturers in Europe witness an increasing use of CDMOs for COVID-19 vaccine production affecting the expansion plans and reducing the flexibility to access existing production slots. Since the outbreak of COVID-19 the vaccine contract manufacturing market, worldwide has experienced significant growth.

Based on state of finished products, the liquid segment is expected to register the largest market share during the forecast period. Moreover, the same segment is estimated to register the highest CAGR during the forecast period. In 2021, the liquid segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 6.0% in the forecast period.

Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., WOCKHARDT, Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH are among the leading companies in the Europe pharmaceutical fill and finish outsourcing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for pharmaceutical fill and finish outsourcing market is segmented into state of finished products and content. Based on state of finished products, the Europe pharmaceutical fill and finish outsourcing market is segmented into solids, semi-liquid and liquid. Based on content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. Geographically, the pharmaceutical fill and finish outsourcing market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com